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Abstract Complex I NADH-oxidoreductase-ubiquinone trans-
ports reducing equivalents from the reduced form of NADH to
ubiquinone (coenzyme Q-CoQ). The purpose of this study was
to analyze mutations in MT-ND1, MT-ND2, MT-ND3 and MT-
ND6 genes and their effect on the biochemical properties, struc-
ture and functioning of proteins in patients with breast tumours.
In researchmaterials, in 50 patients, 28 total polymorphisms and
five mutations were detected. Most detected polymorphisms
(50 %, 14/28) were observed in MT-ND2 gene. Most of them
were silent mutations. Five polymorphisms (m.G3916A,
m.C4888T, m.A4918G, m.C5363T, m.C10283T) do not exist
in the database. A total of five mutations in 13 patients (13/50)
were detected, including two not described in the literature:
m.C4987G andm.T10173C. It cannot be excluded that, through
the mutations and polymorphism impact on the protein struc-
ture, they may cause mitochondrial dysfunction and contribute
to the appearance of other changes inmtDNA. The results of our
study indicate the presence of homological changes in the
sequence of mtDNA in both breast cancer and in some mito-
chondrial diseases. Mutations in the examined genes in breast
cancer may affect the cell and cause its dysfunction, as is the
case in mitochondrial diseases.
Keywords Cancer . Carcinogenesis .Mitochondrial DNA
mutation
Introduction
The participation of mitochondria in tumorigenesis was first
suggested by Warburg in 1932. His explanation was preva-
lence of anaerobic glycolysis in cancer cells. Mitochondrial
DNA is composed of base pairs 16569 (Andrews et al. 1999).
Almost every nucleotide encodes genetic information. The
mtDNA encodes genes for two types of rRNA, 22 types of
tRNA and 13 proteins. Two chains of mtDNA, both light and
heavy, are coding chains. Most of the genes are located in the
heavy chain. The encoded light chain genes are merely the
eight types of tRNA genes and one of the complex I of the
respiratory chain (MT-ND6). The heavy chain of other genes
encodes complex I (MT-ND1, MT-ND2, MT-ND3, MT-ND4,
MT-ND4L and MT-ND5) and the rest of the 13 proteins are
involved in the mitochondrial oxidative phosphorylation
(OXPHOS). In mtDNA the first mutation associated with
cancer was described in renal cell carcinoma (RCC). It con-
cerned the MT-ND1 gene for oxidative phosphorylation
(Welter et al. 1989). The importance of changes taking place
in the mitochondria in the process of carcinogenesis suggests
linking mev −1 mutations in a gene SDHC in Caenorhabditis
elegansare connected with an increased production of reactive
oxygen species (ROS), which are very important factors in the
inactivation of proteins associated with apoptosis and neopla-
sia, such as p 16INK4a and p53 (Grzybowska - Szatkowska
and Slaska 2012a). The purpose of this study was to analyze
mutations in MT-ND1, MT-ND2, MT-ND3 and MT-ND6 genes
and their effect on the biochemical properties, structure and
functioning of proteins in patients with breast tumours.
Material and methods
The tested material was DNA isolated from specimens of
ductal carcinoma (carcinoma ductale) Tp1-2 Np0-1Mp0 and
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blood sampled from 50 patients who had also undergone
surgery for breast cancer. The patients had received no
chemo- or hormonal therapy. They were all perimenopausal.
The blood was taken from each patient and placed in sterile
vacuum test tubes containing dipotassium ethylenediamine-
tetraacetic acid anti-coagulant. The DNAwas isolated with the
use of an automated nucleic acid extraction system-QIACube
(Qiagen, Hilden, Germany). It was extracted from whole
peripheral blood with the QIAamp DNA Blood Mini Kit
(Qiagen), and the QIAamp DNA Blood Kit (Qiagen) was
used for DNA extraction from the tissue. Sequences of MT-
ND1, MT-ND2, MT-ND3, and MT-ND6 genes were analysed
(Table 1). Based on the Homo sapiens mitochondrion, the
complete genome (AC_000021) sequence, primers for the
fragments of test genes (Table 1) were designed with the use
of the Primer3 programme (http://frodo.wi.mit.edu/). The
amplification products were visualised in 2 % agarose gel.
Both strands of the particular genes were sequenced.
Amplicons were sequenced using the BigDye Terminator
Cycle Sequencing Kit (Applied Biosystem, Foster City, CA,
USA) in the GeneAmp PCR system 9700 (Applied
Biosystem). The samples were subsequently purified on
CentriSep columns according to the manufacturer’s protocol
or precipitated with ethanol and sodium acetate according to
the protocol of the BigDye Kit manufacturer. The extension
products were separated on the ABI 377 automated sequencer
(Applied Biosystem). After establishing the consensus
sequence for each analysed sequence, the sequences of the
genes were compared with the Cambridge reference sequence
of the human mitochondrial DNA (AC_000021). The single
nucleotide polymorphisms established for particular gene
fragments were used to identify haplotypes. Polymorphisms
were considered to be changes that occur in both blood/
normal breast cell and tumour cells in the same patient.
Mutation is a change characteristic only for cancer cells and
not occurring in a patient’s blood/normal breast cell.
The impact on the physical and biochemical peptide prop-
erties. The probability of deleterious mutations, i.e. the func-
tional effect of the non-synonymous (amino acid-changing)
protein coding SNP, was determined using the Panther
Classification System (http://www.pantherdb.org/), which
estimates the value of substitution position-specific evolution-
ary conservation (subPSEC) and the probability of a deleteri-
ous effect on protein function (Pdeleterious, Probability of
Functional Impairment) on the basis of the alignment of
evolutionarily determined proteins. PANTHER subPSEC
scores are continuous values from 0 (neutral) to about −10
(most likely to be deleterious); -3 is the previously identified
cutoff point for functional significance. A cutoff of −3 corre-
sponds to a 50 % probability that a score is deleterious. From
this, the probability that a given variant will cause a deleteri-
ous effect on protein function is estimated by Pdeleterious, such
that a subPSEC score of −3 corresponds to a Pdeleterious of 0.5.
The determination of helicity per residue for the peptides was
performed using the AGADIR program (http://agadir.crg.es/).
The GRAVY and the theoretical pI were obtained using the
software program ProtParam tool (http://web.expasy.org/).
The incidence of amino acid in each position of a protein
sequence was assessed using position specific scoring matrix
(PSSM). PSSM scores are generally shown as positive or
negative integers. Positive scores indicate that a given amino
acid substitution occurs more frequently in an alignment than
expected by chance, while negative scores indicate that a
substitution occurs less frequently than expected. Large pos-
itive scores often indicate critical functional residues, which
may signify active site residues or residues required for other
Table 1 Primer sequences used in PCR amplification and sequencing












MT-ND2 Mitochondrially encoded NADH
dehydrogenase 2









MT-ND6 Mitochondrially encoded NADH
dehydrogenase 6
complement (14149..14673) 14051..14073 CCACCTCCATCATCACCTCAAC
14716..14743 GTTCTTGTAGTTGAAATACAACGATGG
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intermolecular interactions (http://www.ncbi.nlm.nih.gov/
Class/Structure/pssm/pssm_viewer.cgi).
The Institutional Review Board at the Medical University
of Lublin specifically approved this study. Approval Number
KE-254/141/2009.
Results
The results are shown in Tables 2, 3, 4 and 5. In the study, 50
patients had a total number of 28 polymorphisms and five
mutations (Table 2). Most polymorphisms (50 %, 14/28)
occurred in the MT-ND2 gene sequence. Most of them were
silent mutations. Five polymorphisms (m.G3916A,
m.C4888T, m.A4918G, m.C5363T, m.C10283T) did not exist
in the database. Polymorphisms m.G3916A, m.C4888T,
m.A4918G, m.C10283T are of the missense type and in the
case of two of them Pdt was above 0.5 which indicates that
those changes are not indifferent to the function of the protein
(Table 4). A total of five mutations were detected in 13
patients (13/50), including two not described in the literature
(m.C4987G, m.T10173C). Only a change of p.C39R in MT-
ND3 seems to have an impact on the functioning of the
protein, Pdt subPSEC=0.86366 -4.84604 (Table 4). The ami-
no acid of cysteine containing sulfhydryl group, which is also
very uncommon in proteins, was replaced here with arginine
containing the guanidine group. This mutation converts a
highly conserved cysteine (PSSM score=11) to argnine
(PSSM score=−5) (Table 5).
Discussion
Mitochondrial electron transport chain consists of four large
complexes of respiratory enzymes. Mutations in the
OXPHOS genes in mtDNA cause disturbances in the trans-
port of electrons through the respiratory chain. Complex I is
called oxidoreductases-NADH-ubiquinone. It consists of sev-
eral flavine mononucelotide polypeptides and iron-sulfur pro-
teins. The purpose of the complex is to transport reducing
equivalents from the reduced form of NADH to ubiquinone
(coenzyme Q-CoQ). Mutations in the genes in mtDNA
OXPHOS cause disturbances in the transport of electrons
through the respiratory chain leading to optic nerve death
and complete blindness (Brown et al. 1992). The severity of
the symptoms depend on the scope and location of the muta-
tion (Komaki et al. 2003; Mitchell et al. 2006; Grzybowska-
Szatkowska and Slaska 2012a).
Although most of the pathogenic mutations in mitochon-
drial diseases are described as homoplasmic, some are also
heteroplasmic.Most occur in LHON (Leber ’s hereditary optic
neuropathy), Kearns - Sayre syndrome (Moraes et al. 1989;
Brown et al. 1992) and in non-insulin dependent diabetes
(Perucca - Lostanlen et al. 2002). They are also described in
canine tumours (Slaska et al. 2013a, b). Tan et al. (2002)
reported in breast cancer four somatic changes in the
OXPHOS system. In three cases they were related to MT-
ND2 (silent mutations). The change in the position
m.T3398C of MT-ND1 described in breast cancer is also
observed in patients with progressive external ophtalmoplegy
and cardiomyopathy (Jaksch et al. 1996; Carelli et al. 2004).
On the other hand, Bai et al. (2000) have found a reduced
expression of mRNA for this complex in the case of mutations
inMT-ND5 complex I in murine lung cancer cells. The authors
believe that it might be caused by disturbances of the regula-
tion of transcription (up- regulation), mRNA stability or im-
pairment of selective degradation of the mutant mRNA.
In breast cancer carcinoma, sequence analysis of all genes
encoding mt-tRNA revealed eight polymorphisms and two
mutations detected in 34 % of the patients (Grzybowska-
Szatkowska and Slaska 2012b). Transitions m.A15924G and
m.A12308G took place only in neoplastic cells, but not in the
blood, so the mutations can be attributed strictly to a neoplas-
tic process. The authors suggest that it may be a result of the
secondary and tertiary tRNA structure and that the polymor-
phisms may lead to mitochondrial dysfunction and contribute
to revealing other changes in mtDNA (Grzybowska-
Szatkowska and Slaska 2012b). Two other polymorphisms
m.G10398A and m.T10400C are also connected with a high
risk of breast cancer (Mims et al. 2005; Czarnecka et al. 2010;
Sultana et al. 2011).
The m.G10398A polymorphism is a marker of haplogroup
IJK. Setiawan et al. (2008) deny the link between the
m.G10398A polymorphism and breast cancer. Also, the poly-
morphism of MT-ND2: m.A4769G and m.G5460A are found
in breast cancer (Czarnecka et al. 2010). In this paper, the
m.G10398A polymorphism was observed in three patients in
the material while m.A4769G was present in 27 cases, and
m.G5460A only in one patient (Table 2). The polymorphism
m.A4769G in contrast to the other two is synonymous, and
does not change the amino acid into the protein. Both the
transition m.G10398A (resulting in the amino acid change
p.T114A) and m.G5460A (resulting in the amino acid change
p.A331T) are not present in a high conservation region and,
by Panther Pdt, it is less than 0.5 (Table 4).
Replacement of polar threonine with alanine causes a re-
duction in the non-polar aliphatic index of the protein and the
amino acid alanine is less preferred in that position than the
threonine (Table 5). The m.G5460A polymorphism is de-
scribed in Alzheimer’s disease (AD), although the relationship
between AD and the polymorphism is being discussed
(Mitchell et al. 2006). The test material (Table 2) also detected
two polymorphisms described in LHON (Johns et al. 1991;
Fauser et al. 2002) and adult onset dystonia. Mitochondrial
haplogroup J/T (Herrnstadt et al. 2002) is defined by the
transition at position m.T4216C. This polymorphism has been
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Table 3 Comparison of protein
properties in non-synonymous















(start and end of helix)
MT-ND1
p.T164A 6.11 123.40 41.94 0.690 H4=0.49 (146–166)
p.E204K 7.85 123.08 41.31 0.681 Mitochondrial matrix
p.T229M 6.11 123.08 44.06 0.690 Mitochondrial matrix
p.Y304K 6.29 123.08 42.69 0.676 H8=3.71 (294–314)
Normal 6.11 123.08 41.94 0.682 H4=0.48
H8=6.59
MT-ND2
p.I57T 9.84 118.10 34.59 0.621 H2=2.91
p.S140L 9.84 120.06 34.10 0.651 H4=0.97 (123–143)
p.N150S 9.84 119.22 34.35 0.644 H5=3.74 (149–169)
p.T173S 9.84 119.22 36.38 0.636 Mitochondrial matrix
p.A331T 9.84 118.93 34.35 0.629 H10=0.37 (326–345)





p.C39R 4.56 46.06 140.00 0.931 Mitochondrial matrix
p.L75V 4.33 52.30 139.13 0.996 H2=4.19 (55–75)
p.T114A 4.33 48.95 140.87 1.014 Mitochondrial matrix
Normal 4.33 50.62 140.00 0.992 H2=4.20
MT-ND6
p.I170V 4.18 28.38 125.17 1.069 H6=0.23 (151–171)
Normal 4.18 29.48 125.75 1.071 N6=0.23
Table 4 Probability of a func-
tional effect on the non-synony-
mous protein-coding SNP
subPSEC Pdeleterious Substitution MSA position Pwt Psubstituted NIC
MT-ND1
−1.55746 0.19115 p.T164A 136 0.11421 0.06006 2.788
−2.97215 0.49304 p.E204K 176 0.46202 0.04771 2.729
−1.76426 0.22518 p.T229M 201 0.0994 0.04119 2.768
−0.92687 0.11174 p.Y304H 276 0.10488 0.06968 1.777
MT-ND2
−2.29998 0.33181 p.I57T 52 0.26164 0.1134 5.16
−3.70833 0.67003 p.S140L 129 0.11788 0.02633 12.218
−3.06754 0.51688 p.N150S 140 0.11018 0.04529 11.003
−2.82675 0.4568 p.T173S 0.81226 0.00678 1.863 0.81226
−2.46689 0.36979 p.A331T 344 0.11939 0.14735 11.076
MT-ND3
−4.84604 0.86366 p.C39R 0.81226 0.00678 1.863 0.81226
−2.64329 0.41176 p.L75V 71 0.59287 0.05843 1.845
−0.64843 0.08694 p.T114A 110 0.24587 0.29884 1.636
MT-ND6
−0.88247 0.1074 p.I170V 0.36272 0.27109 1.92 0.36272
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described as a secondary mutation in LHON (Carelli et al.
2004) and also to be associated with insulin resistance and
type 2 diabetes (Crispim et al. 2006).
This polymorphism relates to helix 8 and changes its per-
centage of 6.59 to 3.71 (Table 3). In insulin resistance and type
2 diabetes it often occurs together with transitions inMT-ND2
at position 4917 (Johns et al. 1991). In the material studied by
us, there was no transition at position 4917, but at position
m.A4918G (Table 2), which resulted in an amino acid change
in the same codon (p.N150S) (Johns et al. 1991; Crispim et al.
2006). This transitionwas accompanied by a polymorphism in
m.T4216C in two patients (Table 2).
Transition m.A4918T is described in the literature as a
natural variant of mtDNA (Marzuki et al. 1991) and it con-
verts a highly conserved arginine containing an amide group
to the serine with a hydroxyl group. Also, the evolutionary
analysis of coding SNPs subPSEC was below −3, indicating
that the polymorphism has an impact on the functioning of the
protein (Table 4). The polymorphism m.T4639C refers to a
highly conserved region and occurs in haplogrup M22
(Table 2), and also relates to the codon described in LHON.
In LHON, polymorphism in that codon concerns mtDNA
position 4640 and there is a replacement of isoleucine with
methionine there (p.I57M) (Volod’ko et al. 2006; Pereira et al.
2011). It should be noted that the substitution of isoleucine for
thereonine will change the percentage of the second helix
down to 2.91 from 12.89 (Table 3). Transition at mtDNA
position 4888 on the MT-ND2 occurred in both tumour cells
and blood so it should be taken as a polymorphism (Table 2).
The polymorphism has not been described so far in the liter-
ature and is not present in the database. It causes a conversion
of polar leucine to nonpolar serine and the evolutionary anal-
ysis of coding SNPs subPSEC was less than −3 (Table 4),
which indicates that the polymorphism is not indifferent to the
functioning of the protein.
The polymorphism m.C3992T is relatively rare in the
general population and when associated with the mitochon-
drial haplogrups of H, T, L (Table 2) it appeared as a mutation
in thyroid cancer (Maximo et al. 2002; Brandon et al. 2006).
We currently know mtDNA genes and regions in which
polymorphisms and mutations are associated with similar
types of cancer in the corresponding tissues of humans and
dogs (Ślaska et al. 2013). In the different types of tumours in
dogs, including breastcancer, there are a number of polymor-
phisms described in the D-loop region, MT-CYTB, MT-COI
and MT-ND1 gene, and a missense mutation in epithelioma
glandulae sebacei resulting in the amino acid change p.T193N
leading to a change in MT-ND1 (Slaska et al. 2013a, b).
Heteroplasmic changes were found in MT-ND1 and MT-
CYTB in epithelioma glandulae sebacei and in MT-CYTB in
lymphoma centroblasticum (Slaska et al. 2013).
Out of the five detected, two mutations were not reported in
the literature. The m.A3796G mutation (resulting in the amino
acid change p.T164A), which is present in the literature, was
described in adult onset dystonia (Simon et al. 2003; Mitchell
et al. 2006). The m.G4580A silent mutation was described in
Table 5 Residue frequencies and PSSM score determined by using
PSSM viewer program
Residue Raw frequency Weighted frequency PSSM score
MT-ND1-MTH00104
p.T164A
T 0.77 0.63 5
A 0.05 0.08 0
p.E204K
E 1.00 1.00 7
K – – 0
p.T229M
T 0.25 0.27 4
M 0.11 0.17 4
p.H304Y
H 0.69 0.54 8
Y 0.24 0.32 6
MT-ND2-MTH00105
p.I57T
T 0.79 0.73 7
I 0.17 0.23 3
p.S140L
S 0.92 0.87 6
L 0.01 0.01 −3
p.N150S
N 0.94 0.90 8
S 0.00 0.01 −1
p.T173S
T 0.98 0.95 7
S 0.00 0.01 0
p.A331T
T 0.10 0.13 2
A 0.01 0.01 −3
MT-ND3-MTH00106
p.C39R
C 1.00 0.99 11
R −5
p.L75V
L 0.99 0.93 6
V −1
p.T114A
T 0.60 0.55 5
A 0.18 0.15 1
MT-ND1-MTH00109
p.I170V
V 0.71 0.52 5
I 0.27 0.44 6
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pancreatic cancer cells (Jones et al. 2001). Both the mutation
m.C4987G (resulting in the amino acid change p.T173S) and
the m.T10173C (resulting in the amino acid change p.C39R)
concern highly conserved aminoacids. Them.C4987Gmutation
occurred in up to ten patients (Table 2). The literature describes
the mutation in the codon 173. Those were related to position
4986. That mutation caused replacement of threonine with
alanine. In the cells of intestinal crypts (Taylor et al. 2003) and
in the case of oral cancer – by proline (Tan et al. 2004).
The mutation m.T14166C (resulting in the amino acid
change p.I70V) was described in neurogastrointestinal mito-
chondrial encephalomyopathy (MNGIE) (Nishigaki et al.
2003). MNGIE is an autosomal recessive disorder caused by
loss-of-function mutations in the gene encoding thymidine
phosphorylase. All changes detected in our study were
homplasmic (Table 2). In case of changes in tumours we often
have to deal with homoplasia. As a result of intramitochondial
selection, the dominance of one type of mtDNA occurs in a
mitochondrion, a so-called functional advantage (Augenlicht
and Heerdt 2001; Jones et al. 2001; Grzybowska-Szatkowska
and Slaska 2012a). During cell division the cell strives to
obtain a prevalence of one type of mRNA (a homoplasmy -
a replicative segregation) (Augenlicht and Heerdt 2001; Jones
et al. 2001; Grzybowska-Szatkowska and Slaska 2012a).
The period required for the replication of segregation to
occur would correspond with the phase of neoplastic transfor-
mation. The homoplasmy can also occur as a result of a
random segregation of mitochondria during cell division
(Coller et al. 2001). In subsequent generations of progenitor
cells heteroplasmy may persist, or by a genetic drift a
homoplasmy may occur (Coller et al. 2001; Jones et al. 2001).
As a result of genetic drift either elimination or stabilisation
of rare variants of mtDNA occurs. It seems that this may be the
cause of carcinogenesis. The occurrence and severity of symp-
toms in mitochondrial diseases depends on the ratio between
the normal and mutated DNA. The dominance of mutant
mtDNA in a cell leads to disturbances in the production of
energy in the process of oxidative phosphorylation, which may
lead to cell and tissue damage. The clinical manifestations of
those disorders depends on the type of defects in the mitochon-
drial DNA and on the degree of sensitivity of the heteroplasmic
tissue disorders related to cellular respiration. When there is an
advantage of mutant mtDNA, symptoms arise that are progres-
sive in character.
Mutations in the genes for mitochondrial proteins cause a
wide range of symptoms. Changes in mtDNA accumulate
with age due to long-term exposure to free radicals generated
in the mitochondria (Liu et al. 1998; Czarnecka and Bartnik
2011). The delayed onset and progressive nature of mitochon-
drial diseases indicate a progressive deterioration with age in
the mitochondrial function (Liu et al. 1998). This is why some
mitochondrial diseases occur in middle or old age (Brown
et al. 1992; Lyamzaev et al. 2004).
In the studied material we detected polymorphisms occur-
ring in patients with LHON syndrome and in adult onset
dystonia. In the phase of clinical detection cancer has about
1 cm3 volume and contains 109 cells. The average time of the
preclinical phase lasts from 15 to 20 years, or much longer,
even 50 years. This raises the question of whether the muta-
tions present in the mitochondrial DNA are primary in relation
to cancer or are the result of changes produced and processes
occurring during carcinogenesis. Their original character is
indicated by their disclosure in the form of clinical signs after
a long period of occurrence (upon reaching the prevalence of
the mutant mtDNA) and the slow progressive nature of the
symptoms as is the case with the mitochondrial diseases.
Open Access This article is distributed under the terms of the Creative
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